| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,025,643 ) |
| | 2025 | 2025 | PLEIOGENIX INC | 2349 SUMMERWIND PL | CARLSBAD | CA | 92008-3796 | SAN DIEGO | USA | R44AA029642 | An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation | 000 | 2 | NIH | 5/14/2025 | $1,025,643 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | PLEIOGENIX INC | 2349 SUMMERWIND PL | CARLSBAD | CA | 92008-3796 | SAN DIEGO | USA | R43AA029642 | An innovative non-thiazolidinedione pan-PPAR agonist therapeutic for Alcoholic Hepatitis | 000 | 1 | NIH | 5/7/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $295,923 ) |
| | 2022 | 2022 | PLEIOGENIX INC. | 2349 SUMMERWIND PL | CARLSBAD | CA | 92008-3796 | SAN DIEGO | USA | R43AA029642 | An innovative non-thiazolidinedione pan-PPAR agonist therapeutic for Alcoholic Hepatitis | 000 | 1 | NIH | 5/12/2022 | $295,923 |
|
|
